XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xeris Biopharma Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.95+0.64 (+6.21%)
Close on Oct 19, 2026
- Market cap
- $1.89B
- P/E (TTM)
- –
- Dividend yield
- –
Xeris Biopharma Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Product revenue, net | $283.00M | $196.64M | $153.36M | $109.26M | $49.28M | 97.0% | +43.9% |
| Recorlev | $139.28M | $64.28M | $29.55M | $7.43M | $0 | 47.7% | +116.7% |
| Gvoke | $94.11M | $82.83M | $67.05M | $52.53M | $38.92M | 32.2% | +13.6% |
| Keveyis | $47.65M | $49.53M | $56.77M | $49.31M | $10.36M | 16.3% | -3.8% |
| Royalty, contract and other revenue | $8.84M | $6.43M | $10.55M | $985.00K | $310.00K | 3.0% | +37.4% |
| Other product revenue | $1.96M | $0 | $0 | – | – | 0.7% | – |
By region
From the segment and revenue-disaggregation notes of Xeris Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.